Objective: The insulin-like growth factor 2 (IGF2) gene is regulated by imprinting in normal tissues. The loss of imprinting (LOI) results in the bi-allelic expression of IGF2. Its increased activity has been associated with many cancers including colorectal cancer (CRC). To investigate the significance of IGF2 in CRC, normal tissue and tumor biopsies from 400 patients were analyzed and correlated with clinical outcome and the KRAS and PIK3 status. Method: The IGF2 820 G/A gene polymorphism and imprinting status were examined by restriction fragment length polymorphism of DNA derived from normal tissues and tumors then of RNA from heterozygous cases. IGF2 protein analysis as well as an RNA microarray were performed. Results: 41 % of the analysed cases were heterozygous. LOI was detectable in both normal tissues and tumors in 60 % of cases. Tumors with LOI had significantly higher IGF2 protein levels. Gene expression analysis revealed significance of cell cycle progression and mitosis genes in LOI. Conclusion: IGF2 LOI is a common and early change in patients with CRC and in normal tissues, provides possibly a preneoplastic change. However increased IGF2 protein levels as well as a different cell cycle specific gene expression profile were detected in tumors with LOI. Future studies must be performed to find out, whether such subsets of tumors differ in their response to chemotherapy or alternative therapies. Objective: Novel high-throughput technologies has revealed numerous genomic abnormalities in B-cell non-Hodgkin lymphomas (NHL). This study aimed to detect point mutations involving EZH2 and CD79B in a population of B-cell NHL by applying a multiplex mutation assay to minimal residual material from needle aspirates, and to determine the evolution of their mutational status overtime using all sorts of available samples from these patients. Method: DNA was extracted from residual cytological material stored on FTA® Cards as well as from archived cytological and histological specimens. The presence of point mutations was investigated by a specifically developed assay utilizing MassARRAY spectrometry and confirmed by direct sequencing. Results: All 121 samples from 80 B-cell NHL cases were successfully analyzed. Mutations in EZH2 (Y641) and CD79B (Y196) were detected in 13.2 % and 8 % of the samples, respectively. Mutational status varied in one third of the positive cases, with either gain or loss of mutations over the course of time. Conclusion: Minimal material from lymph node fine needle biopsy is a reliable source for high-throughput multiplex analysis for the detection of point mutation involving EZH2 and CD79B. Whenever possible, the most recent sample should be tested to verify the current status of the disease.